BioLineRx (BLRX) Reports FY 21 Net Loss of $27.1M

BioLineRx (NASDAQ: BLRX) reported FY 21 net loss of $27.1 million.

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• UBS Reiterates Sell Rating on Macy's (M) on Price Challenges Vs. Peers
• Wall Street on Fed rate hike: 'As hawkish as it gets'